Annexin Pharmaceuticals AB Total Liabilities

Latest as of March 2026: Skr5.56 Million SEK ≈ $598.56K USD

Annexin Pharmaceuticals AB total liabilities. Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.56 Million SEK (≈ $598.56K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Annexin Pharmaceuticals AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Annexin Pharmaceuticals AB (2014–2025)

Total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025. This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data.

Annexin Pharmaceuticals AB Competitors by Total Liabilities

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.

Company	Country	Total Liabilities
Core AI Holdings NASDAQ:CHAI	USA	$22.83 Million
ArcWest Exploration Inc V:AWX	Canada	CA$989.09K
Eversafe Rubber Bhd KLSE:0190	Malaysia	RM48.28 Million
Whitebark Energy Ltd AU:WBE	Australia	AU$5.06 Million
Codrus Minerals Ltd AU:CDR	Australia	AU$140.10K
Marvel Biosciences Corp V:MRVL	Canada	CA$4.33 Million
Destiny Media Technologies Inc V:DSY	Canada	CA$741.04K
Opyl Ltd AU:OPL	Australia	AU$695.82K

Liability Composition Analysis (2014–2025)

This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ANNX asset base.

Liquidity & Leverage Metrics

Annexin Pharmaceuticals AB Total Liabilities Ratios Explained

Annexin Pharmaceuticals AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)

The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr5.22 Million ≈ $562.19K	-1.86%
2024-12-31	Skr5.32 Million ≈ $572.84K	-33.04%
2023-12-31	Skr7.95 Million ≈ $855.44K	+21.81%
2022-12-31	Skr6.53 Million ≈ $702.30K	+7.71%
2021-12-31	Skr6.06 Million ≈ $652.05K	+34.05%
2020-12-31	Skr4.52 Million ≈ $486.42K	-0.59%
2019-12-31	Skr4.55 Million ≈ $489.33K	-26.52%
2018-12-31	Skr6.19 Million ≈ $665.93K	-3.45%
2017-12-31	Skr6.41 Million ≈ $689.71K	-18.72%
2016-12-31	Skr7.88 Million ≈ $848.55K	+140.18%
2015-12-31	Skr3.28 Million ≈ $353.30K	+234.61%
2014-12-31	Skr981.14K ≈ $105.59K	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$4.83 Million

Skr44.86 Million SEK

Market Cap Rank

#28591 Global

#630 in Sweden

Share Price

Skr6.26

Change (1 day)

-4.86%

52-Week Range

Skr6.26 - Skr27.20

All Time High

Skr37.00